Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced a significant development in its partnership with Nestlé Health Science—a non-binding memorandum of understanding whereby Nestlé Health Science will acquire certain tangible and intangible assets related to VOWST (fecal microbiota spores, live-brpk) capsules. This pivotal transaction will grant Nestlé Health Science full control over the development, commercialization, and manufacturing of VOWST both in the United States and globally.

Background and Implications of the Deal

Nestlé Health Science, which has been the lead commercialization party for VOWST since its U.S. launch in June 2023, aims to consolidate its influence over the product’s future following its successful market introduction. VOWST is notable as the first and only orally administered microbiota-based therapeutic approved by the U.S. Food and Drug Administration (FDA) to prevent the recurrence of Clostridioides difficile infection (CDI) in adults following treatment for recurrent CDI (rCDI).

Statements from Corporate Leadership

Moreno Perugini, President of Medical Nutrition and Pharma at Nestlé Health Science, expressed satisfaction with the product’s performance and the ongoing partnership with Seres Therapeutics. “VOWST has been extremely successful since we first made it available to patients in June of last year. We have had a productive collaboration with Seres during the development and FDA approval of VOWST, and we are pleased to continue to provide this important medication to patients,” said Perugini.

Next Steps in the Acquisition Process

The completion of this acquisition is contingent upon the negotiation of definitive agreements, approval by Seres Therapeutics’ shareholders, and fulfillment of other customary conditions. This strategic move is expected to enhance Nestlé Health Science’s portfolio in the medical nutrition and pharmaceutical sectors, reflecting its commitment to expanding innovative health solutions.

Potential Impact on the Pharmaceutical and Healthcare Industries

By acquiring the assets associated with VOWST, Nestlé Health Science is poised to significantly impact the treatment landscape for CDI, particularly in the management of its recurrence. The full control over VOWST’s development and commercialization not only solidifies Nestlé’s standing in the healthcare sector but also emphasizes the importance of advanced therapeutic options in managing complex infections.

  Microbiota-Based Therapy, Nestlé Health Science, pharmaceutical acquisition, Seres Therapeutics, VOWST